X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ophthalmology (1669) 1669
humans (1552) 1552
bevacizumab (1508) 1508
index medicus (1488) 1488
avastin (1336) 1336
male (987) 987
female (978) 978
vascular endothelial growth factor a - antagonists & inhibitors (855) 855
aged (777) 777
middle aged (761) 761
antibodies, monoclonal, humanized (752) 752
macular degeneration (740) 740
endothelial growth-factor (718) 718
ranibizumab (670) 670
angiogenesis inhibitors - administration & dosage (651) 651
angiogenesis inhibitors - therapeutic use (607) 607
treatment outcome (529) 529
intravitreal injections (527) 527
vascular endothelial growth factor (463) 463
injection (446) 446
retrospective studies (438) 438
aged, 80 and over (433) 433
adult (430) 430
injections (427) 427
antibodies, monoclonal - administration & dosage (419) 419
tomography, optical coherence (415) 415
vitreous body (386) 386
fluorescein angiography (375) 375
neovascularization (361) 361
bevacizumab avastin (358) 358
visual acuity - physiology (357) 357
antibodies, monoclonal - therapeutic use (353) 353
follow-up studies (342) 342
choroidal neovascularization (341) 341
intravitreal bevacizumab avastin (326) 326
photodynamic therapy (320) 320
choroidal neovascularization - drug therapy (306) 306
intravitreal bevacizumab (305) 305
diabetic retinopathy (300) 300
therapy (288) 288
eye diseases (285) 285
prospective studies (274) 274
visual acuity (270) 270
angiogenesis (267) 267
macular degeneration - drug therapy (266) 266
animals (255) 255
angiogenesis inhibitors - adverse effects (245) 245
angiogenesis inhibitors (241) 241
vegf (236) 236
age-related macular degeneration (230) 230
macular edema - drug therapy (227) 227
intravitreal injection (226) 226
antibodies, monoclonal, humanized - administration & dosage (225) 225
macular edema (220) 220
verteporfin (211) 211
genetic structures (209) 209
retinopathy (207) 207
care and treatment (205) 205
optical coherence tomography (197) 197
medicine & public health (194) 194
antibodies, monoclonal, humanized - therapeutic use (190) 190
safety (190) 190
choroidal neovascularization - etiology (187) 187
antibodies, monoclonal - adverse effects (179) 179
secondary (179) 179
sense organs (175) 175
retina (172) 172
diabetic retinopathy - drug therapy (170) 170
triamcinolone acetonide (169) 169
pharmacology & pharmacy (166) 166
vitrectomy (164) 164
surgery (161) 161
triamcinolone (148) 148
edema (145) 145
visual acuity - drug effects (140) 140
research (139) 139
cancer (134) 134
pharmacokinetics (132) 132
macular edema - etiology (131) 131
physiological aspects (130) 130
diabetic macular edema (129) 129
anti-vegf (128) 128
choroidal neovascularization - physiopathology (128) 128
combined modality therapy (126) 126
degeneration (125) 125
retinal vein occlusion (121) 121
efficacy (120) 120
drug therapy (119) 119
pegaptanib (118) 118
retina - pathology (118) 118
macular degeneration - complications (116) 116
diabetes (115) 115
abridged index medicus (112) 112
analysis (112) 112
expression (110) 110
vascular endothelial growth factor a - metabolism (106) 106
proliferative diabetic-retinopathy (105) 105
macular degeneration - physiopathology (104) 104
photochemotherapy (101) 101
randomized clinical-trial (101) 101
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2181) 2181
German (82) 82
French (26) 26
Korean (16) 16
Chinese (15) 15
Spanish (14) 14
Portuguese (8) 8
Russian (6) 6
Czech (3) 3
Persian (2) 2
Hungarian (1) 1
Polish (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Ophthalmology, ISSN 0161-6420, 2012, Volume 119, Issue 7, pp. 1399 - 1411
Purpose To compare the efficacy and safety of ranibizumab and bevacizumab intravitreal injections to treat neovascular age-related macular degeneration (nAMD).... 
Ophthalmology | DIABETIC-RETINOPATHY | TRIAL | AVASTIN | DESIGN | OPHTHALMOLOGY | INTRAVITREAL BEVACIZUMAB | CHARTS | Macular degeneration | Chronic diseases | Angiogenesis inhibitors | Universities and colleges
Journal Article
International Heart Journal, ISSN 1349-2365, 2017
Bevacizumab, an inhibitor of vascular endothelial growth factor (VEGF) -A, is currently used to treat patients with ovarian or colon cancer. While several... 
Chemotherapy | VEGF | Avastin
Journal Article
OPHTHALMOLOGY, ISSN 0161-6420, 04/2007, Volume 114, Issue 4, pp. 743 - 750
Purpose: To report the 6-month anatomic and best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin) in patients with... 
OPHTHALMOLOGY | RETINOPATHY | BEVACIZUMAB AVASTIN | INJECTION | ENDOTHELIAL GROWTH-FACTOR
Journal Article
OPHTHALMOLOGY, ISSN 0161-6420, 02/2007, Volume 114, Issue 2, pp. 400 - 401
Journal Article
International Journal of Pharmaceutics, ISSN 0378-5173, 2015, Volume 490, Issue 1-2, pp. 375 - 383
Delivery of drugs, especially bioactive macromolecules such as proteins and nucleic acids, to the posterior segment is still a significant challenge for... 
Posterior segment disorder | Thermosensitive hydrogel | Sustained release | Avastin
Journal Article
Journal of Immunological Methods, ISSN 0022-1759, 2019, Volume 469, pp. 42 - 46
The development of Bevacizumab (Avastin) biosimilar products has grown rapidly over the last ten years as the original Avastin's patent will expire soon. The... 
Sandwich ELISA PK assay | Non-VEGF competing anti-Avastin mAb | Avastin | Bevacizumab | Measurement | Medical research | Biological products | Endothelial growth factors | Monoclonal antibodies | Medicine, Experimental | Enzyme-linked immunosorbent assay
Journal Article
OPHTHALMOLOGY, ISSN 0161-6420, 05/2007, Volume 114, Issue 5, pp. 855 - 859
Purpose: To describe the pharmacokinetics of 1.25 mg of intravitreal bevacizumab (Avastin). Design: Experimental animal study. Participants: Twenty... 
REGRESSION | CLEARANCE | PROLIFERATIVE DIABETIC-RETINOPATHY | INJECTION | COHERENCE TOMOGRAPHY FINDINGS | OPHTHALMOLOGY | MACULAR DEGENERATION | RETINAL VEIN OCCLUSION | BEVACIZUMAB AVASTIN | NEOVASCULARIZATION | SHORT-TERM
Journal Article
مجله دانشکده پزشکی اصفهان, ISSN 1027-7595, 08/2016, Volume 34, Issue 387, pp. 718 - 723
مقدمه: در جراحی Dacryocystorhinostomy به عنوان درمان استاندارد انسداد مجرای اشکی، عوامل مختلفی در پیش‌گیری از عود دخیل هستند. با توجه به ذکر خواص ضد فیبروز... 
Recurrence | Dacryocystorhinostomy | Avastin
Journal Article
Journal of Isfahan Medical School, ISSN 1027-7595, 08/2016, Volume 34, Issue 387, pp. 718 - 723
Journal Article
Angiogenesis, ISSN 0969-6970, 2010, Volume 13, Issue 4, pp. 281 - 292
Photodynamic therapy (PDT) induces damage to the endothelium, which can lead to increased vascular permeability and, under intensive PDT conditions, even to... 
Vimentin | Photodynamic therapy | VEGF | Oncology | Galectin-1 | Real-time RT–PCR | Biomedicine general | Cell Biology | Avastin | Angiogenesis | Visudyne | Biomedicine | Capillary | Cancer Research | Ophthalmology | Cardiology | Real-time RT-PCR | MACULAR DEGENERATION | CAM MODEL | TUMOR ANGIOGENESIS | Avastin (R) | CHOROIDAL NEOVASCULAR MEMBRANES | PHOTOFRIN-II | PHOTOTHROMBIC ACTIVITY | VERTEPORFIN | IN-VIVO | PERIPHERAL VASCULAR DISEASE | Visudyne (R) | EXPRESSION | ENDOTHELIAL GROWTH-FACTOR | Angiogenic Proteins - genetics | Neovascularization, Physiologic - drug effects | Photochemotherapy - adverse effects | Transcription, Genetic - drug effects | Blood Vessels - growth & development | Neovascularization, Physiologic - genetics | Antibodies, Monoclonal - pharmacology | Blood Vessels - metabolism | Angiogenesis Inhibitors - pharmacology | Chorioallantoic Membrane - metabolism | Photosensitizing Agents - adverse effects | Porphyrins - pharmacology | Chick Embryo | Bevacizumab | Gene Expression Regulation - drug effects | Antibodies, Monoclonal, Humanized | Photosensitizing Agents - pharmacology | Animals | Blood Vessels - drug effects | Chorioallantoic Membrane - drug effects | Porphyrins - adverse effects | Angiogenic Proteins - metabolism | Chorioallantoic Membrane - blood supply | Physiological aspects | Genetic aspects | Neovascularization | Research | Photochemotherapy | Cancer | Original Paper
Journal Article
by Wang, J and Qi, L and Liu, L and Wang, ZJ and Chen, G and Wang, Y and Liu, XN and Liu, Y and Liu, HJ and Tong, YX and Liu, C and Lei, CP and Wang, XH
FRONTIERS IN PHARMACOLOGY, ISSN 1663-9812, 08/2019, Volume 10, p. 905
Objective: This study compared the pharmacokinetics (PK), safety, and immunogenicity of the biosimilar TAB008 monoclonal antibody to bevacizumab (AvastiN (R))... 
BLIND | TAB008 monoclonal antibody injection | SAFETY | pharmacokinetics | PHARMACOLOGY & PHARMACY | Avastin (R) | CHINESE PATIENTS | immunogenicity | biosimilarity | Monoclonal antibodies | Dosage and administration | Avastin
Journal Article
European Journal of Ophthalmology, ISSN 1120-6721, 08/2013, Volume 24, Issue 2, pp. 228 - 234
Purpose: To examine the efficacy of monthly injections of intravitreal bevacizumab (IVB) for macular edema after iodine-125 plaque radiotherapy of uveal... 
Eye | Intravitreal bevacizumab (Avastin) | Uvea | Melanoma | Tumor | Macular edema | Anti-vegf | Iodine-125 plaque radiotherapy | MACULOPATHY | AVASTIN | RADIATION RETINOPATHY | SECONDARY | ISCHEMIA | RETINAL VEIN OCCLUSION | Intravitreal bevacizumab ( Avastin) | THERAPY | PHARMACOKINETICS | INJECTION | OPHTHALMOLOGY | Anti-VEGF | ENDOTHELIAL GROWTH-FACTOR
Journal Article
Ophthalmology, ISSN 0161-6420, 07/2019, Volume 126, Issue 7, pp. 1007 - 1015
Intravitreal anti-vascular endothelial growth factor (VEGF) pharmacotherapy has become standard of care for the management of diabetic macular edema (DME). The... 
STROKE | CANCER-PATIENTS | LASER | PHOTOCOAGULATION | OPHTHALMOLOGY | RANDOMIZED-TRIAL | BEVACIZUMAB AVASTIN | AFLIBERCEPT | COMPLICATIONS | RANIBIZUMAB | ENDOTHELIAL GROWTH-FACTOR
Journal Article
The Oncologist, ISSN 1083-7159, 06/2007, Volume 12, Issue 6, pp. 713 - 718
Journal Article
Journal Article